2
Key Points
➤ This guideline update provides evidence-based recommendations
to optimally use currently available biomarkers in the population
of women presenting with early-stage breast cancer with known
estrogen receptor (ER), and human epidermal growth factor receptor
2 (HER2) status.
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-based B Benefits
outweigh
harms
H High Strong
CB/
FC
Consensus-
based/Formal
Consensus
H Harms
outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative
balance of
benefits
and
harms
L Low Weak
N No
recommendation
U Benefits/
harms
ratio
uncertain
Ins Insufficient
